Comparing CPK-NAC levels from baseline to follow-up showed significant improvement (Table 8). However, the patient with anti-synthetase syndrome (anti-PL-7,12 positive) experienced a relapse and subsequently switched to methotrexate, while the other patient with dermatomyositis responded well until the first maintenance dose. The gene discussed is PIK3C2A; the disease is Down syndrome.